The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10820 malaria professionals are enjoying the free benefits of MalariaWorld today

artemether-lumefantrine (AL)

The effect of an anti-malarial subsidy programme on the quality of service provision of artemisinin-based combination therapy in Kenya: a cluster-randomized, controlled trial

March 7, 2013 - 07:12 -- Open Access
Author(s): 
Kangwana BP, Kedenge SV, Noor AM, Alegana VA, Nyandigisi AJ, Pandit J, Fegan GW, Todd J, Snow RW, Goodman CA
Reference: 
Malaria Journal 2013, 12:81 (1 March 2013)
MalariaWorld

Overall, subsidizing ACT and retailer training can significantly increase the percentage of outlets stocking and selling AL for the presumptive treatment of malaria, but further research is needed on strategies to improve the provision of counselling advice to retail customers.

Country: 

Safety and efficacy of pyronaridine-artesunate in uncomplicated acute malaria: an integrated analysis of individual patient data from six randomized clinical trials

February 26, 2013 - 08:28 -- Open Access
Author(s): 
Duparc S, Borghini-Fuhrer I, Craft J, Arbe-Barnes S, Miller RM, Shin C, Fleckenstein L
Reference: 
Malaria Journal 2013, 12:70 (21 February 2013)
MalariaWorld

Pyronaridine-artesunate was well tolerated with no safety concerns with the exception of mostly mild transient rises in transaminases.

Provider knowledge of treatment policy and dosing regimen with artemether-lumefantrine and quinine in malaria-endemic areas of western Kenya

December 31, 2012 - 07:42 -- Open Access
Author(s): 
Watsierah CA, Onyango RO, Ombaka JH, Abong'o BO, Ouma C
Reference: 
Malaria Journal 2012, 11:436 (29 December 2012)
MalariaWorld

Public-sector providers have higher knowledge on treatment policy and dosing regimen on recommended anti-malarials.

Pages

Subscribe to RSS - artemether-lumefantrine (AL)